Michele Balma, Virginia Liberini, Ambra Buschiazzo, Manuela Racca, Alessio Rizzo, Daniele Giovanni Nicolotti, Riccardo Laudicella, Natale Quartuccio, Michelangelo Longo, Giorgia Perlo, Enzo Terreno, Ronan Abgral, Martin William Huellner, Alberto Papaleo, Désirée Deandreis
BACKGROUND: Breast cancer is the most common malignancy in women, with high morbidity and mortality. Molecular alterations in breast cancer involve the expression or upregulation of various molecular targets that can be used for diagnostic nuclear medicine imaging and radiopharmaceutical treatment. Theragnostics is based on the binding of radionuclides to molecular targets. These radionuclides can induce a cytotoxic effect on the specific tumor cell (target) or its vicinity, thus allowing a personalized approach to patients with effective treatment and comparably small side effects...
February 16, 2023: Current medical imaging